Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
Author | Furuya-Kanamori L. |
Author | Doi S.A. |
Author | Onitilo A. |
Author | Akhtar S. |
Available date | 2022-05-31T19:01:29Z |
Publication Date | 2020 |
Publication Name | Expert Opinion on Drug Safety |
Resource | Scopus |
Identifier | http://dx.doi.org/10.1080/14740338.2020.1691167 |
Abstract | Objectives: Recent studies have shown an increase risk of cardiovascular and hematological adverse events associated with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs). The authors hypothesize that the original studies may have produced exaggerated results because of the small baseline risks involved. Methods: A meta-analysis that included 71 trials, 8 different VEGFR-TKIs, and 11 adverse events were re-analyzed. The outcome of interest was re-defined as the complementary outcome (i.e. remaining free of an adverse event). The inverse variance heterogeneity model was used to pool the effect size. Results: VEGFR-TKIs decreased the risk of remaining free of hypertension by 7% (RR 0.93; 95%CI:0.88?0.97). Specific VEGFR-TKIs; pazopanib, regorafenib, and nintedanib were associated with a decrease risk of remaining free of an arterial thrombotic event (RR 0.96; 95%CI:0.93?0.99), thrombocytopenia (RR 0.91; 95%CI:0.89?0.93), and bleeding (RR 0.96; 95%CI:0.93?0.99) respectively. VEGFR-TKIs were not associated with the thrombotic event, myocardial infarction, stroke, venous thrombotic event, pulmonary embolism, left ventricular dysfunction, or QTc interval prolongation. Conclusion: VEGFR-TKIs are associated with a small increase in the risk of patients developing hypertension, arterial thrombotic events, thrombocytopenia, and bleeding. Previous studies overestimated the actual risk associated with VEGFR-TKIs by analyzing the outcome with the lower baseline risk. |
Language | en |
Publisher | Taylor and Francis Ltd |
Subject | axitinib lenvatinib nintedanib pazopanib protein tyrosine kinase inhibitor regorafenib sorafenib sunitinib vandetanib vasculotropin angiogenesis inhibitor protein kinase inhibitor vasculotropin receptor artery thrombosis Article bleeding cardiovascular disease cardiovascular risk hematologic disease human hypertension meta analysis systematic review thrombocytopenia cardiovascular disease hematologic disease Angiogenesis Inhibitors Cardiovascular Diseases Hematologic Diseases Humans Protein Kinase Inhibitors Receptors, Vascular Endothelial Growth Factor |
Type | Article |
Pagination | 223-228 |
Issue Number | 2 |
Volume Number | 19 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Medicine Research [1379 items ]